KYMRHealthcare · BiotechnologyThe 24 Wall Street analysts covering Kymera Therapeutics, Inc. hold a median 12-month price target of $133 — +9.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 22 Aug 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Kymera Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (96): The shares have been drifting up relative to others.
Accruals (33): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on KYMR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +9.9% from it.
Of the 20 most recent actions, 4 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Aug 2026 | Barclays | Maintains | Overweight | $133 → $139 |
| 30 July 2026 | Deutsche Bank | Initiates | Hold | $120 |
| 28 July 2026 | Guggenheim | Maintains | Buy | — |
| 28 July 2026 | Guggenheim | Maintains | Buy | $125 → $135 |
| 16 July 2026 | Mizuho | Maintains | Outperform | $120 → $140 |
| 16 July 2026 | Mizuho | Maintains | Outperform | — |
| 13 July 2026 | RBC Capital | Downgrade | Sector Perform | $106 → $115 |
| 13 July 2026 | RBC Capital | Downgrade | Sector Perform | — |
| 30 June 2026 | B of A Securities | Maintains | Buy | — |
| 29 June 2026 | B. Riley Securities | Maintains | Buy | — |
| 29 June 2026 | Truist Securities | Maintains | Buy | — |
| 26 June 2026 | Canaccord Genuity | Maintains | Buy | — |
| 25 June 2026 | BTIG | Reiterates | Buy | — |
| 6 May 2026 | Canaccord Genuity | Initiates | Buy | — |
| 16 Mar 2026 | Jefferies | Assumes | Buy | $122 → $110 |
| 3 Mar 2026 | UBS | Maintains | Buy | — |
| 2 Mar 2026 | Citigroup | Maintains | Buy | — |
| 2 Mar 2026 | Stephens & Co. | Maintains | Overweight | — |
| 26 Feb 2026 | BTIG | Maintains | Buy | — |
| 26 Feb 2026 | Piper Sandler | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KYMR appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, Kymera Therapeutics, Inc. returned +174.5% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 97% of US stocks
Cheaper than 4% of US stocks
Cheaper than 16% of US stocks
Cheaper than 90% of US stocks
Higher than 98% of US stocks
Higher than 95% of US stocks
Higher than 13% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
Higher than 22% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Kymera Therapeutics, Inc. has a market value of $10.0B and an enterprise value of $9.3B.
Revenue in the twelve months to 30 June 2026: $105.0M. The latest quarter grew 466.4% year on year.
Net income over the same four quarters: −$299.6M, a −285.3% net margin.
Diluted earnings per share, trailing twelve months: $−3.24.
Free cash flow in the twelve months to 30 June 2026: −$238.0M.
Trailing P/E: −32.5×; forward P/E: −24.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Kymera Therapeutics, Inc. employs 273 people — $385K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Kymera Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Kymera Therapeutics beat second-quarter revenue estimates, boosted by milestone payments from Gilead and Sanofi. The company is advancing development of KT-621, with key trial data expected by year-end.
Why it matters — The milestone-driven revenue beat and upcoming KT-621 trial data are central to Kymera's near-term outlook for investors tracking the company.
Kymera Therapeutics held its Q2 2026 earnings call, and a transcript of the call was published by Seeking Alpha. The transcript covers the company's quarterly earnings discussion.
Why it matters — A KYMR watcher would care because the earnings call transcript provides direct insight into the company's latest quarterly financial results and management commentary.
Kymera Therapeutics completed enrollment in its Phase 2b atopic dermatitis trial of KT-621 about six months ahead of schedule. As a result, the company plans to report top-line data by the end of 2026 and could begin Phase 3 development around mid-2027.
Why it matters — Faster-than-expected enrollment could accelerate the development timeline for KT-621, a key pipeline candidate for Kymera.
Kymera Therapeutics reported a Q2 loss of $0.62 per share, narrower than the Zacks Consensus Estimate of a $0.64 loss and ahead of the $0.95 loss a year ago. The report also beat revenue estimates, according to the headline.
Why it matters — KYMR watchers would note that the quarterly loss came in better than both analyst expectations and last year's figure, indicating results ahead of forecasts.
Kymera Therapeutics announced second-quarter 2026 financial results and a business update, reporting $1.5 billion in cash as of June 30, 2026, with a runway into 2029. The company noted completion of enrollment in the KT-621 (STAT6) BROADEN2 Phase 2b atopic dermatitis trial about six months ahead of schedule (data expected by year-end 2026), ongoing KT-621 Phase 2b asthma and KT-579 (IRF5) Phase 1 trials, a started KT-485 (IRAK4) Phase 1 trial by partner Sanofi, and plans for KT-621 Phase 3 atopic dermatitis trials by mid-2027.
Why it matters — KYMR watchers would care because key clinical milestones for KT-621 are ahead of schedule and the company is well capitalized with cash runway into 2029, supporting its pipeline progress.
The 24 Wall Street analysts covering Kymera Therapeutics, Inc. have a median 12-month price target of $133, with estimates ranging from $111 to $155. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 24 analysts covering Kymera Therapeutics, Inc., 21 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kymera Therapeutics, Inc. 74 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Kymera Therapeutics, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).
No one can know that. What the data says: the median 12-month target from 24 analysts implies +9.9% from the last close, and Ticker Nerd's factor model ranks Kymera Therapeutics, Inc. 74 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Kymera Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KYMR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $111 to $155 over the next 12 months.
Kymera Therapeutics, Inc. returned +174.5% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Kymera Therapeutics Inc. is a pioneering biotechnology company focused on the development of targeted protein degradation therapies.
The most recent item we track (Zacks Investment Research, 6 Aug 2026): "KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments". Kymera Therapeutics beat second-quarter revenue estimates, boosted by milestone payments from Gilead and Sanofi. The company is advancing development of KT-621, with key trial data expected by year-end.
Kymera Therapeutics Inc. is a pioneering biotechnology company focused on the development of targeted protein degradation therapies. These therapies are aimed at disease-causing proteins that have traditionally been considered "undruggable." Kymera's primary function is to leverage its proprietary drug discovery platform to design small molecules that harness the cell's natural protein degradation processes, redirecting them to undesirable proteins and proteins involved in various diseases like cancer and immune-inflammatory conditions. This innovative approach holds significant promise for treating a multitude of diseases where conventional drug modalities are ineffective. Notably, Kymera's work impacts the healthcare and pharmaceutical industries by introducing novel therapeutic options and broadening the horizon for drug discovery and development. In the context of the financial market, Kymera Therapeutics represents a key player amid the emerging biotechnology companies that focus on cutting-edge science to address unmet medical needs. As such, it has captured the interest of stakeholders within both the investment community and the healthcare sector, highlighting its potential role in revolutionizing treatment paradigms on a global scale.
CEO Dr. Nello Mainolfi M.D., Ph.D. · 273 employees · United States · https://www.kymeratx.com
